Our Pipeline

FDL has a robust pipeline of CFTR “correctors,” “potentiators,” and “2nd generation modulators” as well as backup compounds for each of these approaches.  FDL169 has been in multiple Phase I clinical trials in both healthy volunteers and patients with CF.  FDL176 is also in clinical development.  We continue to optimize our “second generation correctors”.

Pre-clinical

Lead Identification
Lead Validation
Lead Optimization

Clinical

Pre-clinical Development
Phase 1
Phase 2
  • FDL169: F508del-CFTR Corrector 80%
  • FDL169 Back-up 38%
  • FDL176: CFTR Potentiator 70%
  • FDL176 Back-up 30%
  • Second Generation Modulators 50%

Have an Idea?

We’d love to hear it!

Submit an Idea